keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Gliadin p31-43, an undigested peptide derived from gliadin, prompts an innate immune response in the intestine and disrupts endocytic trafficking. Moreover, its utilization in celiac disease research has proven beneficial.
产品描述 | Gliadin p31-43, an undigested peptide derived from gliadin, prompts an innate immune response in the intestine and disrupts endocytic trafficking. Moreover, its utilization in celiac disease research has proven beneficial. |
体外活性 | Gliadin p31-43 (100?μg/mL; 30 minutes-6 hours) treatment induces the MyD88/TLR7 complexes, and activates downstream signalling by activating MAPKs, ERK, JNK and p38). Gliadin p31-43 increases the levels of the phosphorylated forms of pY-ERK, JNK (pY-JNK) and p38 (pY-p38)[1]. Gliadin p31-43 treatment increases NF-κB phosphorylation in CaCo-2 cells from 0.45?in control cells to 0.86. Gliadin p31-43 treatment induces a significant increase in levels of the MxA protein. The levels of the IFN-α 7 and 17 mRNAs are also analysed after Gliadin p31-43 treatment[1]. In CaCo-2 cells, Gliadin p31-43 localizes to the early endosomes and delays vesicular trafficking. Gliadin p31-43 interferes with the correct localization of the growth factor regulated tyrosine kinase substrate (HRS) to early endosomes, delaying the maturation of the endocytic vesicles[1]. Western Blot Analysis[1]Cell Line: CaCo-2 cells Concentration: 100?μg/mL Incubation Time: 30 minutes, 3 hours, 6 hours Result: Showed the increase in formation of the MyD88/TLR7 complex, and increased in the level of TLR7. |
体内活性 | Gliadin p31-43 (10 μg; intraluminally injection) shows a sequence-specific spontaneous ability to form structured oligomers and aggregates in vitro and induced activation of the apoptosis-associated speck-like (ASC) complex[2]. The increment of IL-1β indicates the activation of the inflammasome caspase-1 pathway in the small intestine mucosa by oral administration of Gliadin p31-43 (20 μg) in wild type C57Bl/6 mice. Gliadin p31-43 has an intrinsic propensity to form oligomers which trigger the NLRP3 inflammasome[2]. |
别名 | Gliadin p31-43 |
分子量 | 1527.703 |
分子式 | C71H102N18O20 |
CAS No. | 176326-01-5 |
keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Gliadin p31-43 176326-01-5 Gliadin p31 43 Gliadin p3143 Gliadin p-31-43 Inhibitor inhibitor inhibit